Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04195763 · ClinicalTrials.gov registry record
Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)
A clinical trial, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- 50
- Enrollment target
NCT04195763: Completed study, sponsored by Alexion Pharmaceuticals.
NCT04195763 is a clinical trial that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04195763 has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
This observational study will evaluate the treatment effect of Strensiq (asfotase alfa) on Patient Reported Outcomes (PROs) in participants diagnosed with pediatric-onset hypophosphatasia (HPP) registered in the patient support program managed by OneSource™.
Interventions
- DRUG asfotase alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-11-06 |
| Est. Completion | 2024-04-12 |
What the finished NCT04195763 record still lists
NCT04195763 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which asfotase alfa is the first listed.
NCT04195763 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04195763 about?
NCT04195763 is a clinical study titled "Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)". This observational study will evaluate the treatment effect of Strensiq (asfotase alfa) on Patient Reported Outcomes (PROs) in participants diagnosed with pediatric-onset hypophosphatasia (HPP) registered in the patient support program managed by OneSource™.
What is the current status of trial NCT04195763?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2019-11-06. Estimated completion is 2024-04-12.
What interventions are being tested in trial NCT04195763?
The interventions under investigation include: asfotase alfa (DRUG).
Who is sponsoring clinical trial NCT04195763?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI